Compounds > levofloxacin
Page last updated: 2024-09-04

levofloxacin and abt 492

levofloxacin has been researched along with abt 492 in 10 studies

Compound Research Comparison

Studies
(levofloxacin)		Trials
(levofloxacin)		Recent Studies (post-2010)
(levofloxacin)		Studies
(abt 492)		Trials
(abt 492)		Recent Studies (post-2010) (abt 492)
4,3465812,209931778

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (60.00)29.6817
2010's1 (10.00)24.3611
2020's3 (30.00)2.80

Authors

AuthorsStudies
Betson, M; Bingham, M; Doyle, P; Hallworth, S; Harvey, R; Huxley, A; Kirk, R; Moat, J; Nelson, G; Pesnot, T; Tait, M1
Akaki, T; Kajitani, H; Sato, K; Shishido, S; Tomioka, H1
Almer, LS; Balli, DJ; Beyer, JM; Cai, Y; Flamm, RK; Hensey-Rudloff, D; Nilius, AM; Shen, LL1
Danziger, LH; Gunderson, SM; Hayes, RA; Quinn, JP1
Arzamastsev, AP; Firsov, AA; Lubenko, IY; Portnoy, YA; Vostrov, SN; Zinner, SH1
Hermsen, ED; Hovde, LB; Konstantinides, GN; Rotschafer, JC1
Alferova, IV; Firsov, AA; Lubenko, IY; Portnoy, YA; Smirnova, MV; Zinner, SH1
Farrell, DJ; Flamm, RK; Huband, MD; Rhomberg, PR1
Boyanova, L; Markovska, R; Marteva-Proevska, Y; Mitov, I; Ouzounova-Raykova, V; Yordanov, D1
Cercenado, E; Cobos, A; Loras, C; Sanz, JC1

Other Studies

10 other study(ies) available for levofloxacin and abt 492

ArticleYear
Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections.
    Bioorganic & medicinal chemistry letters, 2020, 10-15, Volume: 30, Issue:20

    Topics: Anti-Bacterial Agents; Bacterial Infections; Carbon; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Molecular Structure; Neisseria gonorrhoeae; Structure-Activity Relationship

2020
Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
    Antimicrobial agents and chemotherapy, 2000, Volume: 44, Issue:2

    Topics: 4-Quinolones; Aminopyridines; Anti-Infective Agents; Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium tuberculosis; Ofloxacin; Quinolones; Rifamycins

2000
In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.
    Antimicrobial agents and chemotherapy, 2003, Volume: 47, Issue:10

    Topics: Animals; Anti-Bacterial Agents; Bacteria, Anaerobic; Blood Proteins; Ciprofloxacin; DNA Topoisomerases, Type II; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Protein Binding; Quinolones; Rats

2003
In vitro pharmacodynamic activities of ABT-492, a novel quinolone, compared to those of levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
    Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:1

    Topics: Anti-Infective Agents; beta-Lactamases; Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Haemophilus influenzae; Kinetics; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Ofloxacin; Penicillin Resistance; Quinolones; Streptococcus pneumoniae

2004
ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model.
    The Journal of antimicrobial chemotherapy, 2004, Volume: 54, Issue:1

    Topics: Algorithms; Anti-Infective Agents; Area Under Curve; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Half-Life; Humans; Levofloxacin; Models, Biological; Ofloxacin; Protein Binding; Quinolones; Staphylococcus aureus

2004
Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
    Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:4

    Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Quinolones; Respiratory Tract Infections; Streptococcus pneumoniae

2005
Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model.
    International journal of antimicrobial agents, 2005, Volume: 25, Issue:5

    Topics: Anti-Bacterial Agents; Area Under Curve; Ciprofloxacin; Computer Simulation; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Streptococcus pneumoniae; Time Factors

2005
In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:10

    Topics: Anti-Bacterial Agents; Fluoroquinolones; Haemophilus influenzae; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Streptococcus pneumoniae; United States

2016
Activity of delafloxacin versus that of levofloxacin against anaerobic and microaerophilic isolates.
    Anaerobe, 2020, Volume: 62

    Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests

2020
In vitro activity of delafloxacin against highly levofloxacin-resistant invasive isolates of Streptococcus pneumoniae.
    Enfermedades infecciosas y microbiologia clinica (English ed.), 2022, Volume: 40, Issue:3

    Topics: Anti-Bacterial Agents; Fluoroquinolones; Levofloxacin; Streptococcus pneumoniae

2022